Vital Therapies upgraded to Outperform from Market Perform at William Blair
William Blair analyst Y. Katherine Xu upgraded Vital Therapies to Outperform ahead of the VTL-308 readout in September. VTL-308 is the company’s Phase 3 trial designed to evaluate its Elad System in subjects with severe alcoholic hepatitis.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.